NovaBridge Biosciences (NBP) Enterprise Value (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Enterprise Value data on file, last reported at -$210.8 million in Q4 2025.

• Quarterly Enterprise Value fell 21.59% year-over-year to -$210.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$210.8 million (down 21.59% YoY) and the FY2025 annual result came in at -$210.8 million, down 21.59% from the prior year.
• Enterprise Value advanced to -$210.8 million in Q4 2025 per NBP's latest filing, from -$228.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$165.6 million in Q2 2025 and bottomed at -$118.4 billion in Q4 2021.
• The 5-year median for Enterprise Value is -$317.3 million (2023), against an average of -$9.4 billion.
• The widest annual swing landed in 2021, when Enterprise Value plunged 16273.69%; it then soared 99.61% in 2022.
• Tracing NBP's Enterprise Value over 5 years: stood at -$118.4 billion in 2021, then surged by 99.61% to -$465.5 million in 2022, then jumped by 31.84% to -$317.3 million in 2023, then surged by 45.35% to -$173.4 million in 2024, then decreased by 21.59% to -$210.8 million in 2025.
• Per Business Quant, the three latest NBP Enterprise Value figures stand at -$210.8 million (Q4 2025), -$228.3 million (Q3 2025), and -$165.6 million (Q2 2025).

Peer Comparison